Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study Of Inotuzumab Ozogamicin (Cmc-544) In Subjects With Indolent Non-hodgkin's Lymphoma (Nhl) That Is Refractory To Or Has Relapsed After Rituximab And Chemotherapy Or Radioimmunotherapy

NCT00868608 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00868608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00868608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study Of Inotuzumab Ozogamicin (Cmc-544) In Subjects With Indolent Non-hodgkin's Lymphoma (Nhl) That Is Refractory To Or Has Relapsed After Rituximab And Chemotherapy Or Radioimmunotherapy
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
July 30, 2009
Completion date
June 27, 2013
Enrollment
81 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma